Maryland Medical Assistance Program and Health Insurance - Pharmacogenomic Testing - Required Coverage
Summary
SB 961 would require the Maryland Medical Assistance Program (Medicaid) and certain private health plans regulated in Maryland to cover pharmacogenomic testing in specified circumstances. The bill defines pharmacogenomic testing as laboratory genetic testing, including single-gene and multigene panel testing, used to assess how a person’s genetic profile may affect the efficacy, safety, or toxicity of medications. Coverage would be required when the test is ordered by a treating provider for a patient diagnosed with depression or anxiety and the provider is considering a medication change, dose adjustment, or augmentation involving a drug with a known gene-drug interaction.
The bill also limits how prior authorization may be used for this coverage. Insurers, nonprofit health service plans, and HMOs would have to create a clear and timely authorization process, require only the minimum necessary documentation, allow requests from either the treating provider or the laboratory, and avoid administrative barriers that delay care. The bill applies these requirements to carriers and, beginning July 1, 2026, to managed care organizations in Medicaid as well.
Impact
SB 961 would add a new mandated benefit to Maryland insurance law and Medicaid coverage rules by creating Section 15-861 of the Insurance Article and cross-referencing it in the Health-General Article for the Maryland Medical Assistance Program. It would require covered entities to pay for qualifying pharmacogenomic testing and would constrain prior authorization practices for that service. The bill also establishes enforcement tools, including monetary penalties, corrective action plans, administrative hearings, periodic audits, and a reporting process for patients, prescribers, and laboratories. The effective date is October 1, 2025, with Medicaid managed care compliance beginning July 1, 2026.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the available record suggests the bill is framed as a patient-access and precision-medicine measure rather than a controversial restructuring of coverage. Its stated purpose is to improve medication selection and reduce adverse effects for patients with depression or anxiety by using genetic testing to guide treatment. Because there are no transcripts or vote tallies provided, no formal legislative sentiment can be measured from committee debate or floor action in this dataset.
Contention
The main points of potential contention are likely to be cost, utilization management, and the scope of mandated coverage. Insurers and managed care organizations may object to a new required benefit, especially because the bill limits prior authorization and imposes penalties for noncompliance. Another likely issue is the bill’s targeted eligibility standard, which covers only patients with depression or anxiety when a provider is considering a medication change tied to a known gene-drug interaction; supporters may view that as appropriately narrow, while opponents may argue it is either too restrictive or too open-ended depending on implementation. No specific objections or supporters are identified in the provided transcripts or votes.